Literature DB >> 15951833

4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1): a cytotoxic agent towards cancer cells and a probe for tubulin-microtubule system.

Suparna Sengupta1, Sasidharan L Smitha, Nisha E Thomas, Thankaiyyan R Santhoshkumar, Satyabhama K C Devi, Kumaran G Sreejalekshmi, Kallikat N Rajasekharan.   

Abstract

Microtubule binding drugs are of special interest as they have important roles in the modulation of cellular functions and many of them act as anticancer agents. 4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1) was identified as one of the active compounds from a series of diaminoketothiazoles in a cell-based screening assay to discover cytotoxic compounds. DAT1 shows cytotoxicity with GI(50) values ranging from 0.05 to 1 microM in different malignant cell lines with an average value of 0.35 microM. It blocks mitosis in the prometaphase and metaphase stages. In HeLa cells, DAT1 blocks the spindle function by disturbing spindle microtubule and chromosome organization. The drug also inhibits assembly of brain microtubules and binds tubulin specifically at a single site with induction of fluorescence. The dissociation constant of DAT1 binding to tubulin was determined as 2.9+/-1 microM at 24 degrees C. The binding site of DAT1 on tubulin overlaps with that of the conventional colchicine-binding site. DAT1 can thus be considered as a lead compound of a new class of small molecules and this study can be used as a step to develop potent antimitotic agents for the control of cytoskeletal functions and cell proliferation. It would also be an interesting probe for the structure-function studies of tubulin-microtubule system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15951833      PMCID: PMC1576226          DOI: 10.1038/sj.bjp.0706276

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

Review 1.  Tubulin and microtubules as targets for anticancer drugs.

Authors:  John A Hadfield; Sylvie Ducki; Nicholas Hirst; Alan T McGown
Journal:  Prog Cell Cycle Res       Date:  2003

Review 2.  Antimicrotubular drugs binding to vinca domain of tubulin.

Authors:  Suvroma Gupta; Bhabatarak Bhattacharyya
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

Review 3.  The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization.

Authors:  Jesús Jiménez-Barbero; Francisco Amat-Guerri; James P Snyder
Journal:  Curr Med Chem Anticancer Agents       Date:  2002-01

Review 4.  Novel aspects of natural and modified vinca alkaloids.

Authors:  Alain Duflos; Anna Kruczynski; Jean-Marc Barret
Journal:  Curr Med Chem Anticancer Agents       Date:  2002-01

5.  Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

Authors:  Limin Hu; Judith Hofmann; Yiling Lu; Gordon B Mills; Robert B Jaffe
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

Review 6.  Paclitaxel (taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery.

Authors:  Ajay Gautam; Nadezhda Koshkina
Journal:  Curr Cancer Drug Targets       Date:  2003-08       Impact factor: 3.428

7.  Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.

Authors:  Takashi Shingu; Kazuo Yamada; Nobumasa Hara; Kouzo Moritake; Harumi Osago; Masaharu Terashima; Takeshi Uemura; Toshiki Yamasaki; Mikako Tsuchiya
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

8.  Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.

Authors:  S E Holwell; P A Cooper; M J Thompson; G R Pettit; L W Lippert; S W Martin; M C Bibby
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

Review 9.  Docetaxel (taxotere) in the treatment of prostate cancer.

Authors:  Tomasz M Beer; Mohammed El-Geneidi; Kristine M Eilers
Journal:  Expert Rev Anticancer Ther       Date:  2003-06       Impact factor: 4.512

10.  Cross-talk between signalling pathways and the multidrug resistant protein MDR-1.

Authors:  S Ding; M Chamberlain; A McLaren; L Goh; I Duncan; C R Wolf
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

View more
  4 in total

1.  2-Arylamino-4-amino-5-aroylthiazoles. "One-pot" synthesis and biological evaluation of a new class of inhibitors of tubulin polymerization.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Dora Carrion; Olga Cruz-Lopez; Carlota Lopez Cara; Giuseppe Basso; Giampietro Viola; Mohammed Khedr; Jan Balzarini; Siavosh Mahboobi; Andreas Sellmer; Andrea Brancale; Ernest Hamel
Journal:  J Med Chem       Date:  2009-09-10       Impact factor: 7.446

2.  From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules.

Authors:  Andrew Woodland; Raffaella Grimaldi; Torsten Luksch; Laura A T Cleghorn; Kayode K Ojo; Wesley C Van Voorhis; Ruth Brenk; Julie A Frearson; Ian H Gilbert; Paul G Wyatt
Journal:  ChemMedChem       Date:  2013-06-14       Impact factor: 3.466

3.  ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells.

Authors:  Reshma Thamkachy; Rohith Kumar; K N Rajasekharan; Suparna Sengupta
Journal:  Mol Cancer       Date:  2016-03-08       Impact factor: 27.401

4.  Targeting DNA Repair through Podophyllotoxin and Rutin Formulation in Hematopoietic Radioprotection: An in Silico, in Vitro, and in Vivo Study.

Authors:  M H Yashavarddhan; Sandeep K Shukla; Pankaj Chaudhary; Nitya N Srivastava; Jayadev Joshi; Mrutyunjay Suar; Manju L Gupta
Journal:  Front Pharmacol       Date:  2017-10-31       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.